PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease
The PEARL study (CTONG2303) will evaluate efficacy of lorlatinib in CNS metastases in ALK+ NSCLC using refined CNS response evaluation criteria, with biomarker analyses providing insights into response and resistance mechanisms.
Authors
- Chong‐Rui Xu (ORCID: https://orcid.org/0000-0002-3474-2809)
- Yang-Si Li
- Weineng Feng (ORCID: https://orcid.org/0000-0001-5453-8605)
- Bin-Chao Wang
- Xu‐Chao Zhang (ORCID: https://orcid.org/0000-0002-4138-8115)
- Shiyuan Chen (ORCID: https://orcid.org/0000-0001-9805-2906)
- Chang Lu (ORCID: https://orcid.org/0000-0001-6504-6083)
- Yi-Long Lung Cancer Wu (ORCID: https://orcid.org/0000-0002-3611-0258)
- Chanyuan Zhang (ORCID: https://orcid.org/0000-0002-2803-673X)
- Qing Zhou (ORCID: https://orcid.org/0009-0004-8866-8466)
- Guanming Jiang (ORCID: https://orcid.org/0000-0002-1864-4168)
- Hai-Yan Tu
- Wen-Zhao Zhong
- Jin-Ji Yang
- Hong-Hong Yan
Institutions
- First People's Hospital of Foshan (CN)
- Dongguan People’s Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Clinical Lung Cancer
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1016/j.cllc.2024.12.002
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Bureau